Syntegon Group, a strategic partner to the pharmaceutical, biotech, and food industries, reported robust growth and margin expansion in the third quarter of 2025, extending momentum from a strong first half of the year.
Group sales in Q3 rose 19% year-over-year to €448 million, driven by an underlying organic growth rate of 15%. The company’s Pharma segment was the primary contributor, delivering 32% sales growth, including 20% organic growth, fueled by sustained customer demand and new project wins. This performance reflects the successful rollout of innovative technologies aligned with Syntegon’s growth strategy introduced in 2024.
Adjusted EBITDA for the quarter climbed 37% to €75 million, resulting in an EBITDA margin of 16.7%, up 230 basis points from the prior year. Margin expansion was supported by higher volume leverage, operational excellence initiatives, and a strategic emphasis on higher-margin business segments.
Innovation and new solutions continued to drive growth and customer engagement. Integrated vial line growth accelerated following the integration of Telstar, acquired in Q4 2024, which contributed both margin improvement and expansion in its freeze dryer business. The company also saw strong order intake in its ready-to-use syringe business. SynTiso, the industry’s first gloveless, high-speed isolator-integrated fill/finish line, received favorable market reception. In the Food segment, the new SVX platform continued to fuel growth and higher margins with its modular and scalable design.
“Our growth and value-creation strategy is delivering measurable impact and underscores the trust our customers place in Syntegon as their strategic lifecycle partner for mission-critical technologies,” said Torsten Türling, CEO of Syntegon. “With our global footprint and our innovative technologies, we are exceptionally well positioned to capture the long-term growth opportunities in our customer’s industries.”
For the first nine months of fiscal 2025, Syntegon’s sales rose 14% year-over-year, with EBITDA up 40% and a margin of 15.9%, reflecting a 300-basis-point increase. Strong cash flow generation rose 31% compared with the prior year, and the group maintained a book-to-bill ratio of approximately 1.1, supporting continued growth momentum.
Find out more at: https://www.syntegon.com/